True Functional Restoration and Analgesia in Non-Radicular Low Back Pain
Information source: Rehabilitation Institute of Chicago
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Low Back Pain
Intervention: Hydromorphone ER (Drug)
Phase: Phase 4
Sponsored by: Rehabilitation Institute of Chicago
Official(s) and/or principal investigator(s):
Norman Harden, M.D., Principal Investigator, Affiliation: Rehabilitation Institute of Chicago
Amy Kirsling, Email: firstname.lastname@example.org
You are asked to take part in this study because you have chronic, non-radicular low back
pain. This study is done to investigate the pain relieving effects of the study drug Exalgo
(Hydromorphone ER) for people who experience chronic non-radicular low back pain. The
purpose of this research is to look at how the study drug can be used to benefit people who
experience this type of pain. This is a phase IV study done to study the safety and
effectiveness of the drug. At this point the drug has been approved by the Food and Drug
Administration and has been studied in more than 2,000 pain patients in clinical trials,
including individuals with low back pain. About 36 subjects will take part in this study.
Official title: True Functional Restoration and Analgesia in Non-Radicular Low Back Pain: a Prospective Double Blind, Placebo-controlled Study of Hydromorphone ER
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: The efficacy of Exalgo (hydromorphone HCl extended release) in Chronic Non-Radicular Low Back Pain (CNRBP) model syndrome to improve pain, function and activity
Secondary outcome: The relationship between pain ratings and functioning
As a participant in this study, you will be asked to come to the Rehabilitation Institute of
Chicago (RIC), Center for Pain Studies (446 E Ontario St. Suite 1011, Chicago, IL 60611).
Your part in this study will last for 8 weeks and will involve 3 visits to the
Rehabilitation Institute of Chicago and anywhere from weekly phone calls to phone calls
every other day.
If you are in this study, you will be placed in one of two study groups: one group will
receive the study drug and one will receive a placebo. You will be assigned a study group by
chance using a process similar to the flip of a coin. This process is called randomization.
Neither you nor the study staff will select the group you will be in. A placebo looks like
the study drug but is an inactive substance that has no medication. Researchers use a
placebo to see if the study drug works better or is safer than not taking anything. You
will have a 66% chance of getting the study drug. You will receive placebo at some point
during the study but you will not know whether you are receiving placebo or study drug
during the entire study. However, if you have a medical emergency, the investigators can
get this information.
Minimum age: 18 Years.
Maximum age: N/A.
- Meets our criteria for CNRBP: non-radiating (below buttocks), no frank weakness or
atrophy, no sensory or reflex changes
- If female, is not pregnant or breast feeding, and not currently attempting to
conceive; if of childbearing potential, use of a highly effective method of birth
control (as determined by Pl).
- Able to read and speak English and provide informed consent; ages: 18-90.
- Able to understand and comply with all data collection methodology.
- Subjects may continue any non opioid, non acetaminophen stable drug regimen with no
changes during the course of study and not use rescue medications 12 hours before
- Subjects taking opioids must agree to detoxify for the protocol. If they agree they
will detox under the direction of the PI before entering the protocol. They may begin
the acetaminophen rescue med as per the protocol while in detox.
- Must have pain greater than or equal to 5 on a 10 point NRS scale at phone screening,
or pain greater than or equal to 50 on VAS at visit one.
- Subjects with hypersensitivity to Opioids, Acetominophen or Exalgo.
- Subjects with severe or untreated psychiatric disturbance (e. g. mania, depression
[esp suicidality], anxiety, substance dependence).
- Subjects with a clinical diagnosis of fibromyalgia or polymyalgia rheumatica.
- Subjects with severe ongoing or unaddressed medical conditions (e. g. Renal or Hepatic
disease [creatinine>1. 5 ml/dl; AST or ALT> 3x normal limit], uncontrolled
hypertension), pulmonary disease, uncontrolled seizure disorder, gastoparesis or
Locations and Contacts
Amy Kirsling, Email: email@example.com
Rehabilitation Institute of Chicago, Chicago, Illinois 60611, United States; Recruiting
Norman Harden, M.D., Principal Investigator
Site Contact Information
Starting date: October 2011
Last updated: January 8, 2013